Andrew Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrew Lee has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Adam W. Feinberg
Carnegie Mellon University
7 shared publications - Jacqueline M. Bliley
Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA 15213, USA
4 shared publications - Adam Jeffrey Engler
Chien-Lay Department of Bioengineering, UC San Diego, San Diego, California, USA
3 shared publications - Brian D. Coffin
Vascular Medicine Institute, University of Pittsburgh Medical Center
3 shared publications - Daniel John Shiwarski
Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, 15213, USA
3 shared publications - Joshua W. Tashman
Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA 15213, USA
3 shared publications
Latest Publications
- Open Access
Engineering 3D Skeletal Muscle Tissue with Complex Multipennate Myofiber Architectures
The hierarchical architecture of skeletal muscle spans from microscale sarcomeres to macroscale myofibers and is integral to its contractile functionality. Pathologies such as volumetric muscle loss (VML) compromise this structure and destroy the native extracellular matrix (ECM), exceeding the regenerative capacity of endogenous repair mechanisms. Here, we present a novel method for tissue engineering biomimetic three-dimensional (3D) skeletal muscle with complex architectures by leveraging freeform reversible embedding of suspended hydrogels (FRESH) 3D bioprinting of the ECM. Collagen type I scaffolds mimicking diverse muscle architectures— including parallel, unipennate, bipennate, multipennate, and convergent—were designed, FRESH printed, and seeded with C2C12 myoblasts to guide myogenesis. Engineered muscle tissues demonstrated scaffold-mediated alignment and fusion into functional myotubes, exhibiting contractile responses to electrical stimulation with architecture-dependent specific force of ∼1 kN/m 2 and a positive force-frequency relationship. In vivo implantation further revealed scaffold-directed cellular and vascular organization, underscoring the translational potential of this approach. In summary, this study demonstrates the capability to use FRESH 3D bioprinting to engineer physiologically relevant muscle architectures, significantly advancing the design of functional muscle tissues for regenerative medicine and in vitro modeling applications.
Open AccessEngineering 3D Skeletal Muscle Tissue with Complex Multipennate Myofiber Architectures
The hierarchical architecture of skeletal muscle spans from microscale sarcomeres to macroscale myofibers and is integral to its contractile functionality. Pathologies such as volumetric muscle loss (VML) compromise this structure and destroy the native extracellular matrix (ECM), exceeding the regenerative capacity of endogenous repair mechanisms. Here, we present a novel method for tissue engineering biomimetic three-dimensional (3D) skeletal muscle with complex architectures by leveraging freeform reversible embedding of suspended hydrogels (FRESH) 3D bioprinting of the ECM. Collagen type I scaffolds mimicking diverse muscle architectures— including parallel, unipennate, bipennate, multipennate, and convergent—were designed, FRESH printed, and seeded with C2C12 myoblasts to guide myogenesis. Engineered muscle tissues demonstrated scaffold-mediated alignment and fusion into functional myotubes, exhibiting contractile responses to electrical stimulation with architecture-dependent specific force of ∼1 kN/m 2 and a positive force-frequency relationship. In vivo implantation further revealed scaffold-directed cellular and vascular organization, underscoring the translational potential of this approach. In summary, this study demonstrates the capability to use FRESH 3D bioprinting to engineer physiologically relevant muscle architectures, significantly advancing the design of functional muscle tissues for regenerative medicine and in vitro modeling applications.
- Open Access
- 1 December 2023
- Published by AIP Publishing in APL Bioengineering
- Vol. 7 (4) , 046113
FRESH™ 3D bioprinted cardiac tissue, a bioengineered platform for in vitro pharmacology
There is critical need for a predictive model of human cardiac physiology in drug development to assess compound effects on human tissues. In vitro two-dimensional monolayer cultures of cardiomyocytes provide biochemical and cellular readouts, and in vivo animal models provide information on systemic cardiovascular response. However, there remains a significant gap in these models due to their incomplete recapitulation of adult human cardiovascular physiology. Recent efforts in developing in vitro models from engineered heart tissues have demonstrated potential for bridging this gap using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in three-dimensional tissue structure. Here, we advance this paradigm by implementing FRESH™ 3D bioprinting to build human cardiac tissues in a medium throughput, well-plate format with controlled tissue architecture, tailored cellular composition, and native-like physiological function, specifically in its drug response. We combined hiPSC-CMs, endothelial cells, and fibroblasts in a cellular bioink and FRESH™ 3D bioprinted this mixture in the format of a thin tissue strip stabilized on a tissue fixture. We show that cardiac tissues could be fabricated directly in a 24-well plate format were composed of dense and highly aligned hiPSC-CMs at >600 million cells/mL and, within 14 days, demonstrated reproducible calcium transients and a fast conduction velocity of ∼16 cm/s. Interrogation of these cardiac tissues with the β-adrenergic receptor agonist isoproterenol showed responses consistent with positive chronotropy and inotropy. Treatment with calcium channel blocker verapamil demonstrated responses expected of hiPSC-CM derived cardiac tissues. These results confirm that FRESH™ 3D bioprinted cardiac tissues represent an in vitro platform that provides data on human physiological response.
- 1 December 2023
- Published by AIP Publishing in APL Bioengineering
- Vol. 7 (4) , 046113
Open AccessFRESH™ 3D bioprinted cardiac tissue, a bioengineered platform for in vitro pharmacology
There is critical need for a predictive model of human cardiac physiology in drug development to assess compound effects on human tissues. In vitro two-dimensional monolayer cultures of cardiomyocytes provide biochemical and cellular readouts, and in vivo animal models provide information on systemic cardiovascular response. However, there remains a significant gap in these models due to their incomplete recapitulation of adult human cardiovascular physiology. Recent efforts in developing in vitro models from engineered heart tissues have demonstrated potential for bridging this gap using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in three-dimensional tissue structure. Here, we advance this paradigm by implementing FRESH™ 3D bioprinting to build human cardiac tissues in a medium throughput, well-plate format with controlled tissue architecture, tailored cellular composition, and native-like physiological function, specifically in its drug response. We combined hiPSC-CMs, endothelial cells, and fibroblasts in a cellular bioink and FRESH™ 3D bioprinted this mixture in the format of a thin tissue strip stabilized on a tissue fixture. We show that cardiac tissues could be fabricated directly in a 24-well plate format were composed of dense and highly aligned hiPSC-CMs at >600 million cells/mL and, within 14 days, demonstrated reproducible calcium transients and a fast conduction velocity of ∼16 cm/s. Interrogation of these cardiac tissues with the β-adrenergic receptor agonist isoproterenol showed responses consistent with positive chronotropy and inotropy. Treatment with calcium channel blocker verapamil demonstrated responses expected of hiPSC-CM derived cardiac tissues. These results confirm that FRESH™ 3D bioprinted cardiac tissues represent an in vitro platform that provides data on human physiological response.
- Open Access
FRESH™ 3D Bioprinted Cardiac Tissue, a Bioengineered Platform for in vitro Toxicology and Pharmacology
There is critical need for a predictive model of human cardiac physiology in the drug development process for assessment of compound toxicology and pharmacology. In vitro two-dimensional monolayer culture of cardiomyocytes provides biochemical and cellular readouts, and in vivo small and large animal models provide information on systemic cardiovascular response. However, there remains a significant gap in these models due to an incomplete recapitulation of adult human cardiovascular physiology, which results in more difficult safety interpretations. Recent efforts in developing in vitro models from engineered heart tissues have demonstrated potential for bridging this gap using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) in a three-dimensional tissue structure. Here we advance this paradigm by implementing FRESH™ 3D bioprinting to build human cardiac tissues in a medium throughput, well-plate format with controlled tissue architecture, tailored cellular composition, and native-like physiological function, specifically in its adrenergic agonist drug response. To do this, we combined hiPSC-CMs, endothelial cells and fibroblasts in a cellular bioink and FRESH™ 3D bioprinted this mixture in the format of a thin tissue strip stabilized on a tissue fixture. Our results confirmed that FRESH™ 3D bioprinted cardiac tissues could be fabricated directly in a 24-well plate format, were composed of dense and highly aligned hiPSC-CMs at >600 million cells/mL, and within 14 days demonstrated reproducible calcium transients and fast conduction velocity of ∼25 cm/s. Interrogation of these cardiac tissues with the ß-adrenergic receptor agonist isoproterenol showed native-like positive chronotropic and inotropic responses, a combination of responses that is not typically observed in 2D monolayer models or standard 3D engineered heart tissue approaches. These results confirm that FRESH™ 3D bioprinted cardiac tissues represents a novel in vitro platform that enables early in vitro pharmacology and toxicology screening.
Open AccessFRESH™ 3D Bioprinted Cardiac Tissue, a Bioengineered Platform for in vitro Toxicology and Pharmacology
There is critical need for a predictive model of human cardiac physiology in the drug development process for assessment of compound toxicology and pharmacology. In vitro two-dimensional monolayer culture of cardiomyocytes provides biochemical and cellular readouts, and in vivo small and large animal models provide information on systemic cardiovascular response. However, there remains a significant gap in these models due to an incomplete recapitulation of adult human cardiovascular physiology, which results in more difficult safety interpretations. Recent efforts in developing in vitro models from engineered heart tissues have demonstrated potential for bridging this gap using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) in a three-dimensional tissue structure. Here we advance this paradigm by implementing FRESH™ 3D bioprinting to build human cardiac tissues in a medium throughput, well-plate format with controlled tissue architecture, tailored cellular composition, and native-like physiological function, specifically in its adrenergic agonist drug response. To do this, we combined hiPSC-CMs, endothelial cells and fibroblasts in a cellular bioink and FRESH™ 3D bioprinted this mixture in the format of a thin tissue strip stabilized on a tissue fixture. Our results confirmed that FRESH™ 3D bioprinted cardiac tissues could be fabricated directly in a 24-well plate format, were composed of dense and highly aligned hiPSC-CMs at >600 million cells/mL, and within 14 days demonstrated reproducible calcium transients and fast conduction velocity of ∼25 cm/s. Interrogation of these cardiac tissues with the ß-adrenergic receptor agonist isoproterenol showed native-like positive chronotropic and inotropic responses, a combination of responses that is not typically observed in 2D monolayer models or standard 3D engineered heart tissue approaches. These results confirm that FRESH™ 3D bioprinted cardiac tissues represents a novel in vitro platform that enables early in vitro pharmacology and toxicology screening.
- 16 March 2022
- Published by IOP Publishing in Biofabrication
- Vol. 14 (2) , 024106
FRESH 3D bioprinting a contractile heart tube using human stem cell-derived cardiomyocytes
Here we report the 3D bioprinting of a simplified model of the heart, similar to that observed in embryonic development, where the heart is a linear tube that pumps blood and nutrients to the growing embryo. To this end, we engineered a bioinspired model of the human heart tube using freeform reversible of embedding of suspended hydrogels 3D bioprinting. The 3D bioprinted heart tubes were cellularized using human stem cell-derived cardiomyocytes and cardiac fibroblasts and formed patent, perfusable constructs. Synchronous contractions were achieved ∼3–4 days after fabrication and were maintained for up to a month. Immunofluorescent staining confirmed large, interconnected networks of sarcomeric alpha actinin-positive cardiomyocytes. Electrophysiology was assessed using calcium imaging and demonstrated anisotropic calcium wave propagation along the heart tube with a conduction velocity of ∼5 cm s −1 . Contractility and function was demonstrated by tracking the movement of fluorescent beads within the lumen to estimate fluid displacement and bead velocity. These results establish the feasibility of creating a 3D bioprinted human heart tube and serve as an initial step towards engineering more complex heart muscle structures.
- 16 March 2022
- Published by IOP Publishing in Biofabrication
- Vol. 14 (2) , 024106
FRESH 3D bioprinting a contractile heart tube using human stem cell-derived cardiomyocytes
Here we report the 3D bioprinting of a simplified model of the heart, similar to that observed in embryonic development, where the heart is a linear tube that pumps blood and nutrients to the growing embryo. To this end, we engineered a bioinspired model of the human heart tube using freeform reversible of embedding of suspended hydrogels 3D bioprinting. The 3D bioprinted heart tubes were cellularized using human stem cell-derived cardiomyocytes and cardiac fibroblasts and formed patent, perfusable constructs. Synchronous contractions were achieved ∼3–4 days after fabrication and were maintained for up to a month. Immunofluorescent staining confirmed large, interconnected networks of sarcomeric alpha actinin-positive cardiomyocytes. Electrophysiology was assessed using calcium imaging and demonstrated anisotropic calcium wave propagation along the heart tube with a conduction velocity of ∼5 cm s −1 . Contractility and function was demonstrated by tracking the movement of fluorescent beads within the lumen to estimate fluid displacement and bead velocity. These results establish the feasibility of creating a 3D bioprinted human heart tube and serve as an initial step towards engineering more complex heart muscle structures.
- 21 July 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (603)
Dynamic loading of human engineered heart tissue enhances contractile function and drives a desmosome-linked disease phenotype
A dynamic mechanical loading platform was developed to improve contractility of engineered heart tissues and study cardiac disease progression.
- 21 July 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (603)
Dynamic loading of human engineered heart tissue enhances contractile function and drives a desmosome-linked disease phenotype
A dynamic mechanical loading platform was developed to improve contractility of engineered heart tissues and study cardiac disease progression.
- Top Cited Papers
- 2 August 2019
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 365 (6452) , 482-487
3D bioprinting of collagen to rebuild components of the human heart
If I only had a heart: 3D bioprinting is still a fairly new technique that has been limited in terms of resolution and by the materials that can be printed. Lee et al. describe a 3D printing technique to build complex collagen scaffolds for engineering biological tissues (see the Perspective by Dasgupta and Black). Collagen gelation was controlled by modulation of pH and could provide up to 10-micrometer resolution on printing. Cells could be embedded in the collagen or pores could be introduced into the scaffold via embedding of gelatin spheres. The authors demonstrated successful 3D printing of five components of the human heart spanning capillary to full-organ scale, which they validated for tissue and organ function. Science , this issue p. 482 ; see also p. 446
- 2 August 2019
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 365 (6452) , 482-487
Top Cited Papers3D bioprinting of collagen to rebuild components of the human heart
If I only had a heart: 3D bioprinting is still a fairly new technique that has been limited in terms of resolution and by the materials that can be printed. Lee et al. describe a 3D printing technique to build complex collagen scaffolds for engineering biological tissues (see the Perspective by Dasgupta and Black). Collagen gelation was controlled by modulation of pH and could provide up to 10-micrometer resolution on printing. Cells could be embedded in the collagen or pores could be introduced into the scaffold via embedding of gelatin spheres. The authors demonstrated successful 3D printing of five components of the human heart spanning capillary to full-organ scale, which they validated for tissue and organ function. Science , this issue p. 482 ; see also p. 446
- 1 September 2018
- Published by Taylor & Francis
- p. 247-268
3D bioprinting of cardiac muscle tissue
Ischemic heart disease kills millions of people across the world every year and has contributed to >13% of total global deaths in 2012 [1]. The vast majority of these heart diseases are slow, degenerative conditions that eventually lead to heart failure over a period of months to years. Thus, there is time and opportunity to intervene in the disease process and repair the damage. The heart, however, does not have the ability to regenerate or undergo repair that is sufficient to overcome myocardial infarction (MI) or other types of cardiomyopathy. A substantial number of therapies have been developed to mitigate the disease processes, but these efforts generally only slow disease progression. Over the past decade, advances in cardiac tissue engineering have demonstrated that it is possible to generate myocardium-like tissue constructs with structural and functional properties that start to recapitulate native muscle. However, the contractile properties and size have remained limited, demonstrating that significant improvements are still needed. For example, neonatal rat cardiomyocytes have been used to engineer cardiac muscle with electromechanical properties that are comparable to native tissue [2–6] and implanted back into rat heart to augment contractile function. Similar techniques have enabled the engineering of myocardium from embryonic stem cell (ESC)-derived cardiomyocytes as well [7–9]. However, these constructs are often of low density and not well aligned. Further, vascularization is only achieved when constructs are implanted in vivo and/or cocultured with endothelial cells in specific conditions. Thus, organizing cardiomyocytes, and potentially endothelial cells, to approximate or mimic the 3D structure of stereotypical myocardium is still a major and unresolved challenge.
- 1 September 2018
- Published by Taylor & Francis
- p. 247-268
3D bioprinting of cardiac muscle tissue
Ischemic heart disease kills millions of people across the world every year and has contributed to >13% of total global deaths in 2012 [1]. The vast majority of these heart diseases are slow, degenerative conditions that eventually lead to heart failure over a period of months to years. Thus, there is time and opportunity to intervene in the disease process and repair the damage. The heart, however, does not have the ability to regenerate or undergo repair that is sufficient to overcome myocardial infarction (MI) or other types of cardiomyopathy. A substantial number of therapies have been developed to mitigate the disease processes, but these efforts generally only slow disease progression. Over the past decade, advances in cardiac tissue engineering have demonstrated that it is possible to generate myocardium-like tissue constructs with structural and functional properties that start to recapitulate native muscle. However, the contractile properties and size have remained limited, demonstrating that significant improvements are still needed. For example, neonatal rat cardiomyocytes have been used to engineer cardiac muscle with electromechanical properties that are comparable to native tissue [2–6] and implanted back into rat heart to augment contractile function. Similar techniques have enabled the engineering of myocardium from embryonic stem cell (ESC)-derived cardiomyocytes as well [7–9]. However, these constructs are often of low density and not well aligned. Further, vascularization is only achieved when constructs are implanted in vivo and/or cocultured with endothelial cells in specific conditions. Thus, organizing cardiomyocytes, and potentially endothelial cells, to approximate or mimic the 3D structure of stereotypical myocardium is still a major and unresolved challenge.
- Top Cited Papers
- 15 May 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (22) , 5647-5652
Stem cell migration and mechanotransduction on linear stiffness gradient hydrogels
Significance: Mechanobiology is receiving an increasing amount of focus, but the mechanics of cell-substrate behavior are often neglected in cell biology. As such, novel materials and systems that are simple to build and share in a nonengineering laboratory are sorely needed. We have fabricated gradient hydrogels with continuous linear gradients above and below the durotactic threshold, making it possible to pinpoint optimal stiffness values for a wide range of biological phenomena without the confounding effects of durotaxis. This system has the potential for wide adoption in the cell biology community because of its ease of fabrication, simple material ingredients, and wide gradient possibilities in a single well.
- 15 May 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (22) , 5647-5652
Top Cited PapersStem cell migration and mechanotransduction on linear stiffness gradient hydrogels
Significance: Mechanobiology is receiving an increasing amount of focus, but the mechanics of cell-substrate behavior are often neglected in cell biology. As such, novel materials and systems that are simple to build and share in a nonengineering laboratory are sorely needed. We have fabricated gradient hydrogels with continuous linear gradients above and below the durotactic threshold, making it possible to pinpoint optimal stiffness values for a wide range of biological phenomena without the confounding effects of durotaxis. This system has the potential for wide adoption in the cell biology community because of its ease of fabrication, simple material ingredients, and wide gradient possibilities in a single well.
- 1 March 2017
- Published by Elsevier in Current Opinion in Biomedical Engineering
- Vol. 1, 31-37
3D bioprinting from the micrometer to millimeter length scales: Size does matter
- 1 March 2017
- Published by Elsevier in Current Opinion in Biomedical Engineering
- Vol. 1, 31-37
3D bioprinting from the micrometer to millimeter length scales: Size does matter
- Top Cited PapersOpen Access
- 20 May 2016
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 2 (10) , 1781-1786
3D Printing PDMS Elastomer in a Hydrophilic Support Bath via Freeform Reversible Embedding
Polydimethylsiloxane (PDMS) elastomer is used in a wide range of biomaterial applications including microfluidics, cell culture substrates, flexible electronics, and medical devices. However, it has proved challenging to 3D print PDMS in complex structures due to its low elastic modulus and need for support during the printing process. Here we demonstrate the 3D printing of hydrophobic PDMS prepolymer resins within a hydrophilic Carbopol gel support via freeform reversible embedding (FRE). In the FRE printing process, the Carbopol support acts as a Bingham plastic that yields and fluidizes when the syringe tip of the 3D printer moves through it, but acts as a solid for the PDMS extruded within it. This, in combination with the immiscibility of hydrophobic PDMS in the hydrophilic Carbopol, confines the PDMS prepolymer within the support for curing times up to 72 h while maintaining dimensional stability. After printing and curing, the Carbopol support gel releases the embedded PDMS prints by using phosphate buffered saline solution to reduce the Carbopol yield stress. As proof-of-concept, we used Sylgard 184 PDMS to 3D print linear and helical filaments via continuous extrusion and cylindrical and helical tubes via layer-by-layer fabrication. Importantly, we show that the 3D printed tubes were manifold and perfusable. The results demonstrate that hydrophobic polymers with low viscosity and long cure times can be 3D printed using a hydrophilic support, expanding the range of biomaterials that can be used in additive manufacturing. Further, by implementing the technology using low cost open-source hardware and software tools, the FRE printing technique can be rapidly implemented for research applications.
- 20 May 2016
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 2 (10) , 1781-1786
Top Cited PapersOpen Access3D Printing PDMS Elastomer in a Hydrophilic Support Bath via Freeform Reversible Embedding
Polydimethylsiloxane (PDMS) elastomer is used in a wide range of biomaterial applications including microfluidics, cell culture substrates, flexible electronics, and medical devices. However, it has proved challenging to 3D print PDMS in complex structures due to its low elastic modulus and need for support during the printing process. Here we demonstrate the 3D printing of hydrophobic PDMS prepolymer resins within a hydrophilic Carbopol gel support via freeform reversible embedding (FRE). In the FRE printing process, the Carbopol support acts as a Bingham plastic that yields and fluidizes when the syringe tip of the 3D printer moves through it, but acts as a solid for the PDMS extruded within it. This, in combination with the immiscibility of hydrophobic PDMS in the hydrophilic Carbopol, confines the PDMS prepolymer within the support for curing times up to 72 h while maintaining dimensional stability. After printing and curing, the Carbopol support gel releases the embedded PDMS prints by using phosphate buffered saline solution to reduce the Carbopol yield stress. As proof-of-concept, we used Sylgard 184 PDMS to 3D print linear and helical filaments via continuous extrusion and cylindrical and helical tubes via layer-by-layer fabrication. Importantly, we show that the 3D printed tubes were manifold and perfusable. The results demonstrate that hydrophobic polymers with low viscosity and long cure times can be 3D printed using a hydrophilic support, expanding the range of biomaterials that can be used in additive manufacturing. Further, by implementing the technology using low cost open-source hardware and software tools, the FRE printing technique can be rapidly implemented for research applications.